ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IGMS IGM Biosciences Inc

7.70
0.95 (14.07%)
After Hours
Last Updated: 16:00:08
Delayed by 15 minutes

Period:

Draw Mode:

Volume 413,393
Bid Price 6.75
Ask Price 11.00
News -
Day High 7.85

Low
3.81

52 Week Range

High
17.70

Day Low 6.79
Company Name Stock Ticker Symbol Market Type
IGM Biosciences Inc IGMS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.95 14.07% 7.70 16:00:08
Open Price Low Price High Price Close Price Prev Close
6.79 6.79 7.85 7.69 6.75
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,199 413,393 $ 7.50 $ 3,100,418 - 3.81 - 17.70
Last Trade Time Type Quantity Stock Price Currency
16:01:41 60 $ 7.70 USD

IGM Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
446.78M 58.79M - 2.13M -246.42M -4.19 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

IGM Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IGMS Message Board. Create One! See More Posts on IGMS Message Board See More Message Board Posts

Historical IGMS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.189.566.707.59259,500-1.48-16.12%
1 Month8.7810.856.708.56234,134-1.08-12.30%
3 Months10.7117.706.7011.79265,524-3.01-28.10%
6 Months4.3417.703.819.05302,9653.3677.42%
1 Year11.3517.703.819.00295,807-3.65-32.16%
3 Years61.4399.443.8123.46325,904-53.73-87.47%
5 Years18.31127.113.8132.19270,394-10.61-57.95%

IGM Biosciences Description

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Your Recent History

Delayed Upgrade Clock